In the present study, we provided evidence that Dex, an adjuvant drug widely used to reduce adverse reactions to chemotherapy, could promote breast cancer lung metastasis via the PI3K-SGK1-CTGF pathway. Here, SGK1 is linked to breast carcinoma.